Newsletter | July 27, 2020

07.27.20 -- How Heat Bio Was Built Around Its Therapeutic Platform

 
Sponsor
Featured Editorial
Industry Insights
5 Keys To Avoid Drug Development Delays When Using CDMOs

Dealing with CDMOs can be a daunting task for some drug developers. Here are five key factors to keep in mind when trying to troubleshoot drug development delays by selecting the right partner.

Can You Meet The Diverse Manufacturing Needs Of The Biopharma Market?

Meeting the needs of the modern biomanufacturing landscape requires a combination of technology and digital solutions working together to effectively and efficiently meet your goals.

Biosafety Considerations For Single-Use Bioreactors

Single-use bioreactors address some key challenges the industry faces by decreasing time-to-market, reducing validation efforts, increasing flexibility, reducing investment costs, and optimizing cost of goods.

Stirred-Tank Bioreactors For COVID-19 Vaccine Development And Production

Bottlenecks arise from the use of two-dimensional T-flasks and roller bottles. Stirred-tank biological control systems are essential to increased productivity in the development of COVID-19 vaccines.

Scale Your Bioproduction With Large-Format High-Flow Connectors

Looking to scale up your liquid bioprocessing and decrease transfer times? Learn how high-flow, genderless, large-format connectors make scale and efficiency easy and reliable.

Optimization Of Protein A Chromatography For Trastuzumab

Four Protein A resins were screened for use in a capture step for a Herceptin biosimilar. Multiple parameters were assessed for their performance against the platform resin.

Finding Biotech Funding In Volatile Times

Dr. Ben Zeskind founded Immuneering in 2008 as the economy spiraled into the Great Recession. Here, Zeskind tells us how he adjusted his fundraising strategy to build the foundation of a thriving company.

Small Molecule Impurities: A Control System Design Challenge For ADCs

Composed of both antibody and small molecule elements, antibody-drug conjugates (ADCs) have a complex structure from which many different impurities can arise.

Optimizing Small Batch Size To Solve Formulation Challenges

This article describes the use of industrial-scale machines from the very beginning of formulation, resulting in high-quality output for cGMP processes and optimized small-batch production yields.

Why Are Lipid Formulations Commonly Used To Enhance Bioavailability?

A discussion on potential mechanisms of increased absorption with lipid formulations, screening tools used during the development of these formulations, scale up, and industrialization considerations. 

Solutions
Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.